Be part of the knowledge.™

Oncology and Hematology

1892

LikeLikedUnlike

Episodes 1-15 of 258

The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
MinuteCE®
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
- Harry Yoon, MD
  Peer
0.75 program credits
ICI Combination Regimens for First-Line Treatment of Metastatic ESCC
MinuteCE®
ICI Combination Regimens for First-Line Treatment of Metastatic ESCC
- Harry Yoon, MD
  Peer
- Jaffer Ajani, MD
  Peer
0.75 program credits
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
MinuteCE®
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
- Jaffer Ajani, MD
  Peer
0.75 program credits
The Impact of First-Line Treatment on Subsequent Treatment Options for Metastatic ESCC
MinuteCE®
The Impact of First-Line Treatment on Subsequent Treatment Options for Metastatic ESCC
- Harry Yoon, MD
  Peer
- Jaffer Ajani, MD
  Peer
0.75 program credits
MinuteCE®
Differentiating First-Line Treatment Selection: Combination Immunotherapy and Chemotherapy Regimens for Metastatic ESCC
- Harry Yoon, MD
  Peer
- Jaffer Ajani, MD
  Peer
0.75 credits 7 episodes
Strategies for Navigating First-Line Treatment Selection in Metastatic ESCC
MinuteCE®
Strategies for Navigating First-Line Treatment Selection in Metastatic ESCC
- Harry Yoon, MD
  Peer
- Jaffer Ajani, MD
  Peer
0.75 program credits
Effective Monitoring and Management of Adverse Effects in Metastatic ESCC
MinuteCE®
Effective Monitoring and Management of Adverse Effects in Metastatic ESCC
- Harry Yoon, MD
  Peer
- Jaffer Ajani, MD
  Peer
0.75 program credits
Tailoring First-Line Regimens: Patient-Centric Selection in Metastatic ESCC
MinuteCE®
Tailoring First-Line Regimens: Patient-Centric Selection in Metastatic ESCC
- Harry Yoon, MD
  Peer
- Jaffer Ajani, MD
  Peer
0.75 program credits
Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management
CME/CE
Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management
- Elizabeth R. Plimack, MD, MS, FASCO
  Peer
- Shilpa Gupta, MD
  Peer
0.50 credits
Collaborative Insights to Solve the Puzzle of Bladder Cancer
CME/CE
Collaborative Insights to Solve the Puzzle of Bladder Cancer
- Daniel P. Petrylak, MD
  Peer
- Elizabeth R. Plimack, MD, MS, FASCO
  Peer
- Evan Y. Yu, MD
  Peer
1.00 credits
Personalizing Care Within the RCC Treatment Paradigm
CME/CE
Personalizing Care Within the RCC Treatment Paradigm
- Eric Jonasch, MD
  Peer
- Brad McGregor, MD
  Peer
- Ulka Vaishampayan, MBBS
  Peer
1.00 credits
Future Directions of Ovarian Function Suppression: Answering Unmet Needs in Premenopausal HR+ Early-Stage Breast Cancer
MinuteCE®
Future Directions of Ovarian Function Suppression: Answering Unmet Needs in Premenopausal HR+ Early-Stage Breast Cancer
- Sandra Swain, MD
  Peer
- Virginia Kaklamani, MD
  Peer
0.50 program credits
Timing of Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
MinuteCE®
Timing of Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
- Sandra Swain, MD
  Peer
- Virginia Kaklamani, MD
  Peer
0.50 program credits
Duration of Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
MinuteCE®
Duration of Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
- Sandra Swain, MD
  Peer
- Virginia Kaklamani, MD
  Peer
0.50 program credits
Recent Updates on Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
MinuteCE®
Recent Updates on Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
- Sandra Swain, MD
  Peer
- Virginia Kaklamani, MD
  Peer
0.50 program credits

Program Chapters

Segment Chapters

Playlist:

Recommended